Data at the 2022 ASCO Annual Meeting highlight Roche ’s continued commitment to innovation in oncology and personalised healthcare

Pivotal data onglofitamab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, in heavily pre-treated patients with aggressive lymphoma, will be presented as part of our industry-leading haematology portfolioFurther studies exploring broad genomic testing to support informed treatment decisions for patients and advance cancer care approaches will be presentedBasel, 24 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from clinical trials of 18 approved and investigational medicines across more than 20 cancer types will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held 3-7 June, 2022. Roche and its partners will present clinical studies across medicines, comprehensive genomic tests, and real-world data at this year ’s meeting.“At ASCO this year, progress from our portfolio, partnerships and collaborations showcase our commitment to advance innovation in cancer care,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’re especially pleased to present data f rom our broad haematology portfolio, including pivotal data for glofitamab, a potential first-in-class bispecific antibody that may improve the lives of people with heavily pre-treated aggressive lymphoma.”Focusing on improving outcomes in non-Hodgkin lymphomaNew and updated data in non-Hodgkin lymphoma will be presented at ASCO. This includes pivotal data...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news